2025 SITC Primer on Tumor Immunology and Cancer Immunotherapy is an educational program from the Society for Immunotherapy of Cancer (SITC) that supports researchers and clinicians building foundational and advanced knowledge in cancer immunotherapy science.

The Primer is offered in conjunction with SITC's Annual Meeting, bringing together leaders in the field including program committee chairs from the Icahn School of Medicine at Mount Sinai and Massachusetts General Hospital. The program covers core topics in tumor immunology, immune checkpoint therapy, adoptive cell therapy, and clinical translation of cancer immunotherapy.

Eligible participants are early-career researchers, fellows, residents, and clinicians in oncology and immunology. Check SITC's website for 2025 registration, travel support availability, and application details.

Skip auxiliary navigation (Press Enter). Browse Abstracts Access Enduring Materials Buy Merch Don't miss us in Phoenix for SITC 2026. Visit our SITC 2026 site for the latest information on abstracts, registration, and more.

Join us from Nov. 5 to Nov. 9, 2025 to celebrate 40 years of driving breakthroughs in cancer immunotherapy.

Thank you to our SITC 2025 Organizers Annual Program Committee Chair Miriam Merad, MD, PhD, FAIO Icahn School of Medicine at Mount Sinai Annual Program Committee Co-Chair Massachusetts General Hospital Aurélien Marabelle, MD, PhD Icahn School of Medicine at Mount Sinai Laurence Zitvogel, MD, PhD, FAIO Thank you to our SITC 2025 Keynote & Smalley Lecturer Jennifer A.

Wargo, MD, MMSC MD Anderson Cancer Center Targeting the Microbiome to Promote Health and End Cancer Jen Wargo’s career commitment has always been to advance the understanding and treatment of disease through science. After completing her medical degree, she entered surgical residency training at the Massachusetts General Hospital where she became interested in the biology and treatment of cancer.

During her training, she completed two fellowships in surgical oncology with a focus on cancer immunotherapy. She was recruited to MGH in 2008 to join the faculty in the Division of Surgical Oncology and established a translational research laboratory focusing on better understanding response and resistance to treatment for melanoma, pancreatic cancer, and other cancers.

During that time, her laboratory demonstrated that treatment with molecularly targeted therapy could sensitize tumor cells to treatment with immunotherapy, providing the rationale for combined targeted therapy and immunotherapy combinations. She also began studies on the tumor microbiome in pancreatic and other cancers while at Harvard.

Jen was recruited to the University of Texas MD Anderson Cancer Center in 2013 to help lead the Melanoma Moonshot efforts - and also continued important translational research work on targeted therapy, immunotherapy, and the impact of the gut and tumor microbiome in cancer.

Jen is currently a Professor of Surgical Oncology and Genomic Medicine, and the leader of the Platform for Innovative Microbiome and Translational Research (PRIME-TR) at MD Anderson. Importantly, Jen is deeply invested in working with investigators across the institution and across the world to find better ways to treat, intercept, and ultimately prevent cancer. Richard V.

Smalley Memorial Award & Lectureship Ira Mellman, PhD, FAACR, FAIO Parker Institute for Cancer Immunotherapy, Medici Therapeutics The Coming Renaissance of Cancer Immunotherapy Ira Mellman, PhD, is President of Research at the Parker Institute for Cancer Immunotherapy (PICI). A pioneering force in cancer immunology, he brings decades of experience translating fundamental discoveries into transformative therapies.

At PICI, Dr. Mellman is focused on advancing scientific strategy, amplifying cross-institutional collaboration and accelerating the development of immune-based treatments that change outcomes for patients. Dr. Mellman joined PICI after more than 15 years at Genentech, where he most recently served as Vice President of Cancer Immunology.

There, he led groundbreaking research that helped bring forward Tecentriq® (atezolizumab), anti-TIGIT therapies, and patient-specific neoantigen cancer vaccines as well as multiple other first-in-class immunotherapies. Earlier in his career, he spent two decades at Yale University School of Medicine, where he served as Chair of Cell Biology, Scientific Director of the Yale Cancer Center and Sterling Professor.

He is also the co-founder and Chief Scientific Officer of Medici Therapeutics. A world leader in immuno-oncology and cell biology, Dr. Mellman’s scientific contributions span the discovery of endosomes, the elucidation of how dendritic cells initiate immunity or tolerance and the development of the cancer immunity cycle framework.

His work has fundamentally shaped our understanding of immune checkpoint biology and the design of next-generation cancer vaccines. Dr. Mellman is an elected member of the National Academy of Sciences, the American Academy of Arts & Sciences, and the European Molecular Biology Organization. He has served on the editorial boards of Cell, Journal of Experimental Medicine and as Editor-in-Chief of the Journal of Cell Biology.

His honors include the AACR Lloyd J. Old Award for Cancer Immunology, Yale’s Wilbur Cross Medal and SITC’s Richard Smalley Award. He holds a PhD in genetics from Yale University and an AB from Oberlin College & Conservatory, and completed postdoctoral work at The Rockefeller University.

An Invitation to Exhibit at SITC's 40 th Anniversary Annual Meeting Advancing the Science and Application of Cancer Immunotherapy Worldwide Make your mark at the largest cancer immunotherapy conference and exhibit at SITC’s 40 th Anniversary Annual Meeting , hosted by the leading member-driven organization focused on cancer immunotherapy, SITC.

At SITC’s Annual Meeting, we will bring together international leaders from academia, regulatory and government agencies, as well as industry representatives for unmatched education, scientific exchange and networking with the scientists driving the field. If you have a product or service that will advance research or accelerate laboratory results, do not miss this opportunity to exhibit at SITC’s 40 th Anniversary Annual Meeting.

Reservations for returning 2024 exhibitors will open April 3, 2025. New exhibitors can begin applying on April 28. Contact development@sitcancer.

org to receive the most up to date information. Dates subject to change. Biotechnology companies, cancer organizations/foundations, consulting groups, data management companies, informatics/analysis firms, medical device manufacturers, medical equipment suppliers, medical publishers, pharmaceutical companies, research companies/agencies, scientific supply companies, universities/hospitals/research institutions.

Each face-to-face exhibit booth includes an optional virtual booth space to connect with registrants who cannot attend in person. Take advantage of this space to network with attendees, feature resources and publications, highlight posters and symposia, and link to your company website. Contact our Development Team to learn more about exhibiting and/or sponsorship opportunities at SITC 2025.

Please email us at development@sitcancer. org and we will be in touch as soon as possible. We hope to see you in National Harbor!

SITC 2025 provides a multidisciplinary educational and interactive environment focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied cancer immunotherapy.

The Annual Meeting consists of cutting-edge research presentations by experts in the field, oral and poster abstract presentations and ample opportunity for structured and informal discussions, including important networking opportunities. SITC 2025 also includes updates on major national and international initiatives from academia, government and industry, as well as important society projects.

The audience includes basic and clinical investigators from academic institutions, industry and regulatory agencies, including clinicians, basic and translational researchers, graduate students, post-doctoral fellows, and allied health professionals involved in cancer research as well as pharmacists and payers, who wish to learn more about cancer immunology and immunotherapy and its incorporation into current (and future) effective cancer treatment.

Members receive a substantial discount on SITC 2025 regular registration rates. The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven society dedicated to professionals working in the field of cancer immunotherapy.

Our mission is to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. We aim to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.

I-O Progress and Potential Get a head start on the celebration with a special series of commentaries in the Journal for ImmunoTherapy of Cancer ( JITC ) written by luminaries in the field of immuno-oncology. Drs. Elizabeth Jaffee, Steven Rosenberg, Suzanne Topalian, Giorgio Trinchieri, Theresa Whiteside, and numerous other SITC Fellows of the Academy of Immuno-Oncology (FAIO) and Richard V.

Smalley Memorial Award recipients put pen to paper to provide their insights into current achievements in various areas of the field while also sharing their personal, forward-looking vision of where the field is moving in the upcoming decades. Check out the JITC Special Series Collection throughout 2025 for new publications. 555 East Wells Street, Suite 1100 Email: info@sitcancer.

org Phone: USA Tel: +1 414 271 2456